Literature DB >> 23438075

Wenxin Keli suppresses ventricular triggered arrhythmias via selective inhibition of late sodium current.

Xiaolin Xue1, Donglin Guo, Hongmei Sun, Dan Wang, Jiana Li, Tengxian Liu, Lin Yang, Juan Shu, Gan-Xin Yan.   

Abstract

BACKGROUND: Wenxin Keli is a popular Chinese herb extract that approximately five million Asians are currently taking for the treatment of a variety of ventricular arrhythmias. However, its electrophysiological mechanisms remain poorly understood. METHODS AND
RESULTS: The concentration-dependent electrophysiological effects of Wenxin Keli were evaluated in the isolated rabbit left ventricular myocytes and wedge preparation. Wenxin Keli selectively inhibited late sodium current (INa) with an IC50 of 3.8 ± 0.4 mg/mL, which was significantly lower than the IC50 of 10.6 ± 0.9 mg/mL (n = 6, P < 0.05) for the fast INa. Wenxin Keli produced a small but statistically significant QT prolongation at 0.3 mg/mL, but shortened the QT and Tp-e interval at concentrations ≥ 1 mg/mL. Wenxin Keli increased QRS duration by 10.1% from 34.8 ± 1.0 ms to 38.3 ± 1.1 ms (n = 6, P < 0.01) at 3 mg/mL at a basic cycle length of 2,000 ms. However, its effect on the QRS duration exhibited weak use-dependency, that is, QRS remained less changed at increased pacing rates than other classic sodium channel blockers, such as flecainide, quinidine, and lidocaine. On the other hand, Wenxin Keli at 1-3 mg/mL markedly reduced dofetilide-induced QT and Tp-e prolongation by attenuation of its reverse use-dependence and abolished dofetilide-induced early afterdepolarization (EAD) in four of four left ventricular wedge preparations. It also suppressed digoxin-induced delayed after depolarization (DAD) and ventricular tachycardias without changing the positive staircase pattern in contractility at 1-3 mg/mL in a separate experimental series (four of four).
CONCLUSIONS: Wenxin Keli suppressed EADs, DADs, and triggered ventricular arrhythmias via selective inhibition of late INa. ©2013, The Authors. Journal compilation ©2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23438075     DOI: 10.1111/pace.12109

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  16 in total

Review 1.  Mechanisms and Drug Development in Atrial Fibrillation.

Authors:  David Calvo; David Filgueiras-Rama; José Jalife
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 2.  Pharmacological Therapy in Brugada Syndrome.

Authors:  Oholi Tovia Brodie; Yoav Michowitz; Bernard Belhassen
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-06

3.  Mechanisms underlying atrial-selective block of sodium channels by Wenxin Keli: Experimental and theoretical analysis.

Authors:  Dan Hu; Hector Barajas-Martínez; Alexander Burashnikov; Brian K Panama; Jonathan M Cordeiro; Charles Antzelevitch
Journal:  Int J Cardiol       Date:  2016-01-07       Impact factor: 4.164

4.  Wenxin Keli versus Sotalol for Paroxysmal Atrial Fibrillation Caused by Hyperthyroidism: A Prospective, Open Label, and Randomized Study.

Authors:  Zhaowei Meng; Jian Tan; Qing He; Mei Zhu; Xue Li; Jianping Zhang; Qiang Jia; Shen Wang; Guizhi Zhang; Wei Zheng
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-17       Impact factor: 2.629

5.  Expert Consensus on Wenxin Granule for Treatment of Cardiac Arrhythmias.

Authors: 
Journal:  Chin Med J (Engl)       Date:  2017-01-20       Impact factor: 2.628

6.  Comparative metabonomics of Wenxin Keli and Verapamil reveals differential roles of gluconeogenesis and fatty acid β-oxidation in myocardial injury protection.

Authors:  Miaomiao Jiang; Qiuying Wang; Jingrui Chen; Yanan Wang; Guanwei Fan; Yan Zhu
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

7.  Wenxin Keli for atrial fibrillation: Protocol for a systematic review and meta-analysis.

Authors:  Zhuogen He; Minan Zheng; Pingchang Xie; Yuanping Wang; Xia Yan; Dingwei Deng
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

Review 8.  Therapeutic Effects of Wenxin Keli in Cardiovascular Diseases: An Experimental and Mechanism Overview.

Authors:  Guihua Tian; Yang Sun; Shuo Liu; Chengyu Li; Shiqi Chen; Ruijin Qiu; Xiaoyu Zhang; Youping Li; Min Li; Hongcai Shang
Journal:  Front Pharmacol       Date:  2018-09-05       Impact factor: 5.810

Review 9.  Therapeutic Effects of Traditional Chinese Medicine on Cardiovascular Diseases: the Central Role of Calcium Signaling.

Authors:  Yuxin Li; Zhang Zhang; Sen Li; Tingting Yu; Zhaoqi Jia
Journal:  Front Pharmacol       Date:  2021-07-09       Impact factor: 5.810

10.  The Efficacy and Safety of Wenxin Keli in Patients with Frequent Premature Ventricular Contractions: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial.

Authors:  Wei Hua; Run-Lin Gao; Bu-Chang Zhao; Jing Wang; Xu-Hua Chen; Chi Cai; Shu Zhang
Journal:  Chin Med J (Engl)       Date:  2015-10-05       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.